Video
The Impact of Ongoing Delays in Cancer Screenings in 2021 on Patient Health, Health Systems
Christopher Mast, MD, vice president of clinical informatics at Epic, explains the level to which cancer screening rates would need to rise to meet pre-pandemic rates.
Pharmacy Times interviewed Christopher Mast, MD, vice president of clinical informatics at Epic, on research demonstrating that despite cancer screening rates rebounding in 2021 from the low rates at the beginning of the pandemic, they were still lower than experts in the field had expected.
During the discussion, Mast addressed the impact of these ongoing delays in cancer screenings on patients and health care systems, as well as explained the level to which cancer screening rates would need to increase to meet pre-pandemic levels.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa
